These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16651802)

  • 1. [Neuropeptide receptors: novel therapeutic targets for depression].
    Chaki S; Okuyama S
    Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):196-200. PubMed ID: 16651802
    [No Abstract]   [Full Text] [Related]  

  • 2. Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression.
    Poretti MB; Sawant RS; Rask-Andersen M; de Cuneo MF; Schiöth HB; Perez MF; Carlini VP
    Psychopharmacology (Berl); 2016 Mar; 233(6):1077-86. PubMed ID: 26700241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single administration of interleukin-1 increased corticotropin releasing hormone and corticotropin releasing hormone-receptor mRNA in the hypothalamic paraventricular nucleus which paralleled long-lasting (weeks) sensitization to emotional stressors.
    Schmidt ED; Aguilera G; Binnekade R; Tilders FJ
    Neuroscience; 2003; 116(1):275-83. PubMed ID: 12535959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
    Griebel G; Holsboer F
    Nat Rev Drug Discov; 2012 May; 11(6):462-78. PubMed ID: 22596253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
    Holmes A; Heilig M; Rupniak NM; Steckler T; Griebel G
    Trends Pharmacol Sci; 2003 Nov; 24(11):580-8. PubMed ID: 14607081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The corticotropin-releasing factor receptor: a novel target for the treatment of depression and anxiety-related disorders.
    Grigoriadis DE
    Expert Opin Ther Targets; 2005 Aug; 9(4):651-84. PubMed ID: 16083336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of leptin action in chicken hypothalamus.
    Dridi S; Swennen Q; Decuypere E; Buyse J
    Brain Res; 2005 Jun; 1047(2):214-23. PubMed ID: 15907812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a novel vasopressin V1b receptor antagonist, V1B-30N, in animal models of anxiety-like and depression-like behavior.
    Hodgson RA; Mullins D; Lu SX; Guzzi M; Zhang X; Bleickardt CJ; Scott JD; Miller MW; Stamford AW; Parker EM; Varty GB
    Eur J Pharmacol; 2014 May; 730():157-63. PubMed ID: 24602808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An orally active corticotropin releasing factor 1 receptor antagonist from 8-aryl-1,3a,7,8-tetraaza-cyclopenta[a]indenes.
    Han X; Civiello R; Pin SS; Burris K; Balanda LA; Knipe J; Ren S; Fiedler T; Browman KE; Macci R; Taber MT; Zhang J; Dubowchik GM
    Bioorg Med Chem Lett; 2007 Apr; 17(7):2026-30. PubMed ID: 17258456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression.
    Duman RS; Kehne JH
    CNS Neurol Disord Drug Targets; 2007 Jun; 6(3):161-2. PubMed ID: 17511613
    [No Abstract]   [Full Text] [Related]  

  • 12. The neurobiology of depression: inroads to treatment and new drug discovery.
    Nemeroff CB; Vale WW
    J Clin Psychiatry; 2005; 66 Suppl 7():5-13. PubMed ID: 16124836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of CRF1 receptor antagonists as antidepressants and anxiolytics: progress to date.
    Valdez GR
    CNS Drugs; 2006; 20(11):887-96. PubMed ID: 17044726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic activation of NPFFR2 stimulates the stress-related depressive behaviors through HPA axis modulation.
    Lin YT; Liu TY; Yang CY; Yu YL; Chen TC; Day YJ; Chang CC; Huang GJ; Chen JC
    Psychoneuroendocrinology; 2016 Sep; 71():73-85. PubMed ID: 27243477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ghrelin effects expression of several genes associated with depression-like behavior.
    Poretti MB; Rask-Andersen M; Kumar P; Rubiales de Barioglio S; Fiol de Cuneo M; Schiöth HB; Carlini VP
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Jan; 56():227-34. PubMed ID: 25286107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression.
    Alonso R; Griebel G; Pavone G; Stemmelin J; Le Fur G; Soubrié P
    Mol Psychiatry; 2004 Mar; 9(3):278-86, 224. PubMed ID: 14699428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment.
    Stout SC; Owens MJ; Nemeroff CB
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1085-92. PubMed ID: 11861819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the CRF
    Wróbel A; Serefko A; Szopa A; Rojek K; Poleszak E; Skalicka-Woźniak K; Dudka J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Aug; 390(8):769-774. PubMed ID: 28429110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin.
    Wigger A; Sánchez MM; Mathys KC; Ebner K; Frank E; Liu D; Kresse A; Neumann ID; Holsboer F; Plotsky PM; Landgraf R
    Neuropsychopharmacology; 2004 Jan; 29(1):1-14. PubMed ID: 12942143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRF receptors as a potential target in the development of novel pharmacotherapies for depression.
    Valdez GR
    Curr Pharm Des; 2009; 15(14):1587-94. PubMed ID: 19442175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.